Ivosidenib companion diagnostic - Abbott/Agios

Drug Profile

Ivosidenib companion diagnostic - Abbott/Agios

Alternative Names: AG 120 companion diagnostic

Latest Information Update: 24 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories; Agios Pharmaceuticals
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Acute myeloid leukaemia

Most Recent Events

  • 20 Jul 2018 Registered for Acute myeloid leukaemia (Diagnosis) in USA (unspecified route) - First Global Approval (9245261; 9245259)
  • 15 Feb 2018 Preregistration for Acute myeloid leukaemia (Diagnosis) in USA (unspecified route)
  • 12 Oct 2016 Clinical trials in Acute myeloid leukaemia (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top